Abbott Laboratories (ABT) Non-Current Debt (2009 - 2026)

Abbott Laboratories has disclosed Non-Current Debt across 18 years of filings, most recently posting $29.6 billion for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $29.6 billion, up 132.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.6 billion (up 132.71% YoY), and the FY2025 annual result was $9.9 billion, down 21.62% from the prior year.
• Non-Current Debt came in at $29.6 billion for Q1 2026 at Abbott Laboratories, up from $9.9 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $29.6 billion in Q1 2026 to a low of $9.9 billion in Q4 2025.
• The 5-year median for Non-Current Debt is $13.6 billion (2023), against an average of $14.6 billion.
• Across the five-year window, Non-Current Debt slipped 21.62% in 2025 and soared 132.71% in 2026, its largest moves.
• Abbott Laboratories' Non-Current Debt stood at $14.5 billion in 2022, then decreased by 6.36% to $13.6 billion in 2023, then decreased by 7.16% to $12.6 billion in 2024, then dropped by 21.62% to $9.9 billion in 2025, then surged by 199.49% to $29.6 billion in 2026.
• The last three Non-Current Debt figures came in at $29.6 billion (Q1 2026), $9.9 billion (Q4 2025), and $11.6 billion (Q3 2025), per Business Quant data.